CJC-1295

Safety Risk (2.8/5.0). The catastrophic signal is Gene Larew's death during ConjuChem Phase II (attributed to pre-existing CV conditions), which ended the program. The slower risk is chronic IGF-1 elevation: Endogenous Hormones Collaborative (Lancet Oncol 2010) documented RR 1.28 (95% CI 1.14-1.44) per SD increase in IGF-1 for breast cancer, with comparable associations for colorectal and prostate. DAC produces sustained non-pulsatile IGF-1 elevation for 9-11 days per dose, theoretically amplifying this signal relative to pulsatile endogenous biology. Mod-GRF 1-29 is closer to endogenous patterns and likely safer. Sackmann-Sala 2015 flagged ADA emergence as a class concern. Per v0.5 catastrophic-floor rules the score sits at 2.8, below the 4.0 floor, because the cancer signal is epidemiological rather than proven causal from CJC-1295.

Side Effect Profile (2.5/5.0). Water retention and peripheral edema are the most consistent reports, dose-dependent and typically resolving within 2-3 weeks of stabilization. Carpal tunnel symptoms, joint pain, and flushing (especially with the DAC variant) occur at meaningful frequency per community reporting. Hunger spikes are common because IGF-1 and GH both influence appetite signaling. Injection site reactions include transient redness, bruising, and occasional lipohypertrophy at repeated sites. Ipamorelin stacking adds mild head-rush and tingling within minutes of injection but does not raise cortisol or prolactin per Raun 1998 characterization. GI events are minimal. Per v0.5 framing, side effects sit in the moderate range and are independent of the safety catastrophic concern scored above.

Financial Cost (2.5/5.0). Gray-market peptide vendors run $80-200 per month depending on variant, dose, and stack. A typical Mod-GRF 1-29 + ipamorelin stack at 100 mcg of each 2-3x daily comes to roughly $120-180 per month at mid-tier vendor pricing. DAC variant runs higher per mg but dosed weekly, so monthly cost is broadly similar. Third-party HPLC purity testing, cold-chain shipping, and endotoxin verification add cost at top-tier vendors but are not consistent across the gray market. Per v0.5 accessible-channel rules, scored at the gray-market channel that virtually all users actually access. No insurance coverage, no HSA/FSA eligibility, no compounding pharmacy option in the US for true CJC-1295 (tesamorelin is available by prescription at far higher retail cost).

Time/Effort Burden (3.5/5.0). Mod-GRF 1-29 dosing requires 2-3 subcutaneous injections per day, typically pre-bed, upon waking, and post-workout. That is 14-21 injections per week plus reconstitution, rotation of injection sites, refrigeration of reconstituted vials, and sourcing of sterile supplies (insulin syringes, bacteriostatic water, alcohol swabs). Each injection takes 60-90 seconds once technique is dialed in but the cumulative daily friction is meaningful compared to oral dosing. DAC variant reduces to 1-2 injections per week but with the sustained IGF-1 trade-off most users now avoid. Cycling logistics add complexity: 8-12 weeks on, 4+ weeks off, with purchasing, reconstituting, and storing a 10-12 week peptide supply ahead of each cycle. Not remotely comparable to a daily capsule.

Opportunity Cost (2.0/5.0). GH optimization is achievable through non-peptide levers: sleep hygiene and slow-wave-sleep optimization (the natural endogenous GH pulse channel), resistance training and sprint work (acute GH pulses), fasting windows (growth hormone sensitivity), and protein quality. These produce smaller magnitude signals than exogenous GHRH agonism but carry zero IGF-1/cancer tail risk and zero injection burden. For most healthy adults under 40 these non-peptide levers are unexploited and represent the first-line opportunity. The OC score is moderate because the levers exist but are not perfectly substitutable; exogenous GHRH agonism produces a larger pharmacological signal than any lifestyle intervention can match at the upper end, and for someone already optimizing sleep and training, the next marginal unit of GH biology sits with secretagogues.

Dependency/Withdrawal (1.5/5.0). No reward-circuit hijack, no craving, no tolerance escalation in the addiction sense. The mild functional-dependency signal is hypothalamic-pituitary feedback adaptation: sustained GHRH stimulation can blunt endogenous GHRH receptor sensitivity over prolonged continuous use, which is the rationale for 4-week off-cycles. Chronic somatostatin feedback can dampen the pulse amplitude response. These adaptations reverse with washout. No GH-secretagogue-specific withdrawal syndrome has been documented in the literature. Contrast with GLP-1 agonists (functional weight-regain dependency) or thyroid hormone (true axis suppression): CJC-1295 dependency is a mild receptor-desensitization pattern, not physiological dependence.

Reversibility (1.2/5.0). DAC variant has a half-life of 7-10 days (Teichman 2006) so plasma clearance is complete within 4-6 weeks of cessation. Mod-GRF 1-29 has a half-life under 30 minutes so systemic clearance is complete within 24-48 hours of the last injection. Elevated IGF-1 returns to baseline within 2-4 weeks after the DAC variant and within days after the no-DAC variant. Body composition and sleep benefits fade over weeks to months post-cessation per tesamorelin class reversal data (Falutz 2010 follow-up). No permanent tissue remodeling, no mitochondrial memory, no epigenetic lock-in. Any effects gained during a cycle are accessible only while dosing continues, which is the structural trade-off of the entire GH-secretagogue class.